Macular Degeneration News and Research

Latest Macular Degeneration News and Research

Phase 2 study results: VEGF Trap-Eye improves vision in patients with DME

Regeneron Pharmaceuticals, Inc. and Bayer HealthCare AG announced that VEGF Trap-Eye showed positive results in a Phase 2 study in patients with diabetic macular edema (DME).

18 Feb 2010

UWM engineer creates software program that foresees outcome before stem cell divides

A software program created by an engineer at the University of Wisconsin-Milwaukee (UWM) can not only predict the types of specialized cells a stem cell will produce, but also foresee the outcome before the stem cell even divides.

17 Feb 2010

Quark Pharmaceuticals' QPI-1002 receives orphan drug designation from FDA

Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, announced today that the US FDA has granted orphan drug designation for QPI-1002 (also referred to as "I5NP"), a synthetic siRNA targeting p53 mRNA for the prophylaxis of delayed graft function (DGF) in kidney transplant patients.

17 Feb 2010

pSivida reports consolidated net loss of $24,000 for quarter ended December 31, 2009

pSivida Corp. , a drug delivery company with two of the only three ophthalmic sustained release delivery products approved by the FDA for treatment of back-of-the-eye diseases, today announced financial results for its second quarter and six months ended December 31, 2009.

12 Feb 2010

Scientists uncover new gene that could help save sight of patients with inherited blindness

The international research team led by the University of Leeds found that the TSPAN12 gene is faulty in patients with a disease known as FEVR (Familial Exudative Vitreoretinopathy), which affects the development of the eye.

12 Feb 2010

LUHS nurses earn professional certifications

Several Loyola University Health System (LUHS) nurses have earned professional certifications in their clinical areas of expertise. This indicates that LUHS nurses meet strong professional development standards and competencies.

11 Feb 2010

Sequenom CMM licenses rights from Optherion to develop and commercialize AMD diagnostic tests

Sequenom, Inc., today announced an exclusive worldwide licensing agreement with Optherion, Inc. Under the agreement, Sequenom's CAP accredited and CLIA-certified laboratory, Sequenom Center for Molecular Medicine (Sequenom CMM), obtained the rights to develop and commercialize diagnostic tests to predict genetic predisposition to late stage age-related macular degeneration (AMD).

10 Feb 2010

Thrombogenics announces publication of positive microplasmin Phase II trial results

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, announces today that the positive microplasmin Phase II trial results, evaluating the product's efficacy and safety in patients who require vitrectomy, have been published in the prestigious American Academy of Ophthalmology's Journal, Ophthalmology, the leading journal for the vitreoretinal community.

9 Feb 2010

ZeaVision launches online campaign to raise awareness on Age-related Macular Degeneration

ZeaVision, LLC launched a unique online campaign to increase awareness about Age-related Macular Degeneration during February for AMD Awareness Month.

6 Feb 2010

Paloma Pharmaceuticals receives FDA approval to enter Phase I studies with P529

Paloma Pharmaceuticals, Inc. announced today that it has received acceptance of its IND to enter Phase I studies with Palomid 529 (P529) in patients with age-related macular degeneration (AMD).

5 Feb 2010

Low Vision of Michigan introduces new device for RP patients

To commemorate Low Vision Awareness Month this February, Dr. Sheldon Smith, optometrist at Low Vision of Michigan, P.C., is offering free evaluations to patients diagnosed with retinitis pigmentosa (RP), a leading cause of low vision, in hopes that they might be candidates for a brand-new device designed to enhance or restore sight.

4 Feb 2010

GTRI researchers design arthritis simulation gloves to meet the needs of consumers with functional limitations

As the U.S. population ages, manufacturers of consumer goods are realizing that many customers may not be as nimble-fingered or sharp-sighted as they once were.

4 Feb 2010

ChemoCentryx announces the initiation of Phase I clinical trial of CCX168

ChemoCentryx, Inc., today announced the initiation of a Phase I clinical trial of CCX168, an orally-administered small molecule designed to treat autoimmune diseases.

28 Jan 2010

Researchers to test newest implant in restoring vision damaged by disease

Researchers trying to restore vision damaged by disease have found promise in a tiny implant that sows seeds of new cells in the eye.

28 Jan 2010

Researchers develop PEG-POD tool for gene therapy

Researchers at Tufts University School of Medicine and the Sackler School of Graduate Biomedical Sciences at Tufts have developed a new tool for gene therapy that significantly increases gene delivery to cells in the retina compared to other carriers and DNA alone, according to a study published in the January issue of The Journal of Gene Medicine.

28 Jan 2010

FDA clears Notal Vision's ForeseeHome AMD Monitor

Notal Vision's ForeseeHome™ AMD Monitor has received Section 510 (k) clearance from the U.S. Food and Drug Administration (FDA).

27 Jan 2010

Breakthrough discovery could lead to new treatments for a variety of CNS disorders

A breakthrough discovery by scientists at the University of Kentucky could someday lead to new treatments for a variety of diseases of the brain, spinal cord and the eye.

18 Jan 2010

Laureate Pharma and Iconic Therapeutics complete manufacturing hI-con1 recombinant Fc-Factor VII fusion protein

Laureate Pharma, Inc., a full-service biopharmaceutical development and protein production company specializing in the development and GMP manufacture of monoclonal antibodies, fusion proteins and other therapeutic protein products, and Iconic Therapeutics, a company focused on the development of treatments for wet adult macular degeneration (wet AMD) and other ophthalmic diseases, today announced the completion of the manufacture of the first GMP lot of hI-con1(TM) recombinant Fc-Factor VII fusion protein.

8 Jan 2010

IBI initiates Phase 2/3 pivotal clinical trial to assess the safety and efficacy of IBI-10090

Icon Bioscience, Inc., (IBI), a privately held biopharmaceutical company that specializes in the development and commercialization of novel ophthalmic pharmaceuticals announced today that it has initiated its Phase 2/3 pivotal clinical trial to assess the safety and efficacy of IBI-10090 in patients undergoing cataract surgery.

6 Jan 2010

Enrollment for sham-controlled study of radiation therapy for treatment of wet AMD announced

Oraya Therapeutics, Inc., announced today that enrollment is now underway for the first ever masked and sham-controlled study to demonstrate the efficacy and safety of radiation therapy for the treatment of wet age-related macular degeneration (AMD).

6 Jan 2010

Macular Degeneration News and Research

Latest Macular Degeneration News and Research

Phase 2 study results: VEGF Trap-Eye improves vision in patients with DME

UWM engineer creates software program that foresees outcome before stem cell divides

Quark Pharmaceuticals' QPI-1002 receives orphan drug designation from FDA

pSivida reports consolidated net loss of $24,000 for quarter ended December 31, 2009

Scientists uncover new gene that could help save sight of patients with inherited blindness

LUHS nurses earn professional certifications

Sequenom CMM licenses rights from Optherion to develop and commercialize AMD diagnostic tests

Thrombogenics announces publication of positive microplasmin Phase II trial results

ZeaVision launches online campaign to raise awareness on Age-related Macular Degeneration

Paloma Pharmaceuticals receives FDA approval to enter Phase I studies with P529

Low Vision of Michigan introduces new device for RP patients

GTRI researchers design arthritis simulation gloves to meet the needs of consumers with functional limitations

ChemoCentryx announces the initiation of Phase I clinical trial of CCX168

Researchers to test newest implant in restoring vision damaged by disease

Researchers develop PEG-POD tool for gene therapy

FDA clears Notal Vision's ForeseeHome AMD Monitor

Breakthrough discovery could lead to new treatments for a variety of CNS disorders

Laureate Pharma and Iconic Therapeutics complete manufacturing hI-con1 recombinant Fc-Factor VII fusion protein

IBI initiates Phase 2/3 pivotal clinical trial to assess the safety and efficacy of IBI-10090

Enrollment for sham-controlled study of radiation therapy for treatment of wet AMD announced

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Macular Degeneration News and Research

Latest Macular Degeneration News and Research

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Newsletters you may be interested in